Clinical Trials

Several clinical trials sponsored by academic and hospital institutions have evaluated mannan-related pathways across critical care and infectious disease management. A completed Phase 3 study evaluated treatment strategies for patients at risk of invasive fungal infections, whereas an academic study with a non-applicable trial phase and unknown recruitment status investigated the complement lectin pathway in resuscitated out-of-hospital cardiac arrest patients. Together, these trials highlight the clinical relevance of mannan recognition and MBL pathway assessment in conditions such as post-cardiac arrest syndrome and invasive candidiasis.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02826057 Unknown status
Out-of-Hospital Cardiac Arrest|Post Cardiac Arrest Syndrome
University of Aarhus
2016-02 Not Applicable
NCT01773876 Completed
Invasive Candidiasis
University Hospital Grenoble
2012-07 Phase 3

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Mannan product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Mannan serves as a primary yeast cell wall ligand that binds mannose-binding lectin (MBL), activating the complement lectin pathway and promoting immunomodulatory and antiproliferative cellular responses. This biochemical cascade is clinically relevant in assessing inflammatory and immune responses in post-cardiac arrest syndrome as well as modulating host defense against fungal pathogens in invasive candidiasis.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.